Literature DB >> 4026274

Simultaneous determination of dacarbazine, its photolytic degradation product, 2-azahypoxanthine, and the metabolite 5-aminoimidazole-4-carboxamide in plasma and urine by high-pressure liquid chromatography.

D Fiore, A J Jackson, M S Didolkar, V R Dandu.   

Abstract

A high-pressure liquid chromatographic method has been developed that allows for the simultaneous analysis of dacarbazine (DTIC), 5-aminoimidazole-4-carboxamide (AIC), and 2-azahypoxanthine (2-AZA) in plasma or urine. Plasma samples were prepared by ultrafiltration, whereas urine samples were filtered and diluted for analysis. Chromatography was done with a C18 mu Bondapak column along with gradient elution of the drugs. The mobile phase consisted of 100% 0.5 M sodium acetate (pH 7.0) and 25% acetonitrile in 0.05 M sodium acetate (pH 5.5) with detection at 280 nm. Linearity was observed up to 500 micrograms/ml for DTIC and up to 53 micrograms/ml for AIC and 2-AZA. The assay methodology was reproducible, with a lower limit of detection of 5.0, 0.5, and 0.5 micrograms/ml for DTIC, AIC, and 2-AZA, respectively. Interday and intraday coefficients of variation ranged between 4 to 14% and 2 to 16%, respectively. The analytical method was applied to the analysis of plasma and urine samples resulting from the isolation perfusion chemotherapy of an extremity with 57 mg of DTIC per kg in a patient with melanoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4026274      PMCID: PMC180202          DOI: 10.1128/AAC.27.6.977

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  Pharmacologic studies of the antitumor agent 5-(dimethyltriazeno)imidazole-4-carboxamide.

Authors:  T L Loo; J K Luce; J H Jardine; E Frei
Journal:  Cancer Res       Date:  1968-12       Impact factor: 12.701

2.  Pharmacokinetics of dacarbazine (DTIC) and its metabolite 5-aminoimidazole-4-carboxamide (AIC) following different dose schedules.

Authors:  H Breithaupt; A Dammann; K Aigner
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  Isolated extremity perfusion with DTIC. An experimental and clinical study.

Authors:  K Aigner; P Hild; H Breithaupt; M Hundeiker; K Schwemmle; K Henneking; L Illig; G Merker; E Paul; J Brodkorb; A Jungbluth
Journal:  Anticancer Res       Date:  1983 Mar-Apr       Impact factor: 2.480

  3 in total
  5 in total

1.  Pharmacokinetics of dacarbazine (DTIC) in pregnancy.

Authors:  Ira Kantrowitz-Gordon; Karen Hays; Olumide Kayode; Aditya R Kumar; Henry G Kaplan; Joel M Reid; Stephanie L Safgren; Matthew M Ames; Thomas R Easterling; Mary F Hebert
Journal:  Cancer Chemother Pharmacol       Date:  2018-01-05       Impact factor: 3.333

Review 2.  Therapeutic drug monitoring in oncology. Problems and potential in antineoplastic therapy.

Authors:  M J Moore; C Erlichman
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

3.  Enhancement of temozolomide stability by loading in chitosan-carboxylated polylactide-based nanoparticles.

Authors:  Antonio Di Martino; Pavel Kucharczyk; Zdenka Capakova; Petr Humpolicek; Vladimir Sedlarik
Journal:  J Nanopart Res       Date:  2017-02-16       Impact factor: 2.253

4.  Validated spectral manipulations for determination of an anti-neoplastic drug and its related impurities including its hazardous degradation product.

Authors:  Ibrahim A Naguib; Eglal A Abdelaleem; Eman S Hassan; Aml A Emam
Journal:  RSC Adv       Date:  2021-06-16       Impact factor: 3.361

5.  Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.

Authors:  Imanol Arozarena; Ibai Goicoechea; Oihane Erice; Jennnifer Ferguson; Geoffrey P Margison; Claudia Wellbrock
Journal:  Mol Cancer       Date:  2014-06-19       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.